Lewati ke konten

Informasi medis independen untuk pasien internasional

Menu

Penyakit

Stomach cancer

ICD-10: C16 — Malignant neoplasm of stomach

Kelompok: Kanker Spesialisasi: Bedah Gastrointestinal

Angka utama

Hanya nilai yang diterbitkan. Setiap ubin membuka bagian yang memuat sumber, tahun, dan kalibernya.

Rincian penyakit

Nama Inggris
Malignant neoplasm of stomach

Juga dikenal sebagai

  • Gastric cancer
  • Gastric adenocarcinoma

Kisaran biaya pengobatan

Setiap kisaran di bawah diterbitkan pada satu dasar penagihan: Sebelum penggantian asuransi. Sumber tidak menerbitkan angka setelah penggantian, jadi tidak ada yang ditampilkan di sini.

Jalur pengobatan Kisaran biaya Dasar harga Tahun data
Pembedahan 54000 – 80040 CNY Harga paket per penyakit 2020–2025
Radioterapi 42000 – 50000 CNY Harga per item 2025–2026
Kemoterapi 6550 – 9500 CNY Harga paket per penyakit 2020–2021
Terapi bertarget 84000 – 105000 CNY Harga per item 2024–2025
Imunoterapi 36720 – 145080 CNY Harga per item 2024–2025

Batang-batang berbagi satu skala di seluruh baris di atas: masing-masing dimulai dari angka terbit terendah baris itu dan berakhir pada angka tertingginya. Angka tertinggi di halaman ini adalah 145080 CNY. Setiap baris mempertahankan tahun data dan kalibernya sendiri.

5 kisaran biaya untuk penyakit ini, dengan sumbernya di halaman baris.

Nilai yang ditulis dalam bahasa Tiongkok dikutip sebagaimana diterbitkan oleh sumber.

Lihat semua kisaran biaya →

Kelangsungan hidup lima tahun

Tingkat kelangsungan hidup 5 tahun 35.2% IK 95% 35.0–35.4

Populasi
Keseluruhan (semua stadium digabung) · Tingkat kelangsungan hidup relatif terstandar usia
Periode
2019–2021
Penerbit
Pusat Kanker Nasional Tiongkok
Sifat nilai
Nilai estimasi (analisis campuran)
Cakupan registri
281 registri kanker berbasis populasi
Ketersediaan data stadium
Tidak diterbitkan

Nilai yang ditulis dalam bahasa Tiongkok dikutip sebagaimana diterbitkan oleh sumber.

Lihat semua tingkat kelangsungan hidup →

Cara membaca angka ini. Angka ini diterbitkan untuk semua stadium digabung, jadi ini rata-rata atas semua orang dalam data registri nasional, bukan prognosis untuk satu orang. Pada sebagian besar kanker, stadium saat diagnosis adalah faktor tunggal terkuat di balik perbedaan kelangsungan hidup: kelangsungan hidup umumnya lebih tinggi bila kanker ditemukan pada stadium lebih dini dan lebih rendah bila ditemukan lebih lambat. Perbandingan antar kanker juga dipengaruhi oleh seberapa dini atau lambat masing-masing cenderung didiagnosis, jadi angka yang lebih rendah tidak dengan sendirinya berarti mutu layanan yang lebih buruk.

Angka itu adalah kelangsungan hidup relatif: angka ini membandingkan orang yang didiagnosis kanker ini dengan orang seusia dan sejenis kelamin dalam populasi umum, dan distandardisasi menurut umur, jadi bukan proporsi pasien yang masih hidup setelah lima tahun. Angka ini diterbitkan sebagai nilai perkiraan (analisis hibrida) karena laporan registri datang dengan jeda, sehingga National Cancer Center memodelkan periode terakhir. Sebagai konteks, sumber yang sama menerbitkan kelangsungan hidup relatif lima tahun 43,7% untuk semua kanker gabungan pada 2019–2021.

Rumah sakit dengan catatan terbit untuk penyakit ini

Dipilih menggunakan sumber data publik resmi

Rumah sakit ini dipilih dari sumber data publik resmi — peringkat reputasi spesialisasi rumah sakit Universitas Fudan, daftar spesialisasi klinis kunci nasional, dan pusat riset klinis nasional — sehingga setiap baris pada kartu dapat diperiksa terhadap sumber terbitnya. Ini bukan daftar berbayar atau promosi.

Bagaimana rumah sakit ini dipilih

Penerimaan. Sebuah rumah sakit dicantumkan untuk suatu penyakit bila spesialisasi tempat penyakit itu dikelompokkan memuat paling sedikit satu dari: posisi atau nominasi dalam peringkat reputasi spesialisasi rumah sakit Universitas Fudan; catatan spesialisasi klinis kunci nasional pada tingkat A, B, atau C; atau pusat riset klinis nasional atau laboratorium kunci negara pada spesialisasi itu. Akreditasi JCI ditampilkan sebagai lencana; akreditasi itu tidak pernah menentukan penerimaan dan tidak pernah menentukan urutan.

Urutan. Langkah 1: posisi Fudan antara 1 dan 10 untuk spesialisasi itu. Langkah 2: posisi Fudan lain, atau nominasi. Langkah 3: spesialisasi klinis kunci nasional tingkat A. Langkah 4: spesialisasi klinis kunci nasional tingkat B. Langkah 5: pusat riset klinis nasional atau laboratorium kunci negara pada spesialisasi itu, pusat sebelum laboratorium. Langkah 6: spesialisasi klinis kunci nasional tingkat C, yaitu catatan yang kami terbitkan tanpa sumber resmi independen sehingga dicantumkan setelah yang lain.

Seri. Dalam satu langkah: posisi Fudan yang lebih baik lebih dahulu, lalu tingkat spesialisasi kunci yang lebih kuat (A sebelum B sebelum C), lalu provinsi, lalu kota, lalu nama rumah sakit - urutan provinsi-kota-nama yang sama seperti yang dipakai direktori rumah sakit. Paling banyak delapan rumah sakit dicantumkan.

Bila daftar pendek. Lima rumah sakit atau lebih: delapan yang pertama dicantumkan. Tiga atau empat: semuanya dicantumkan, dan satu lipatan tambahan menambahkan catatan sisanya sampai delapan, masing-masing membawa tingkat buktinya. Satu atau dua: sama, dengan lipatan itu terbuka dan satu baris yang menyatakan berapa rumah sakit yang memiliki catatan publik kuat. Tidak ada: halaman menyatakan bahwa tidak ditemukan catatan publik kuat dan menautkan ke direktori spesialisasi. Posisi, lembaga, atau jumlah tidak pernah diciptakan untuk mengisi daftar.

Peringkat Fudan adalah peringkat reputasi spesialisasi rumah sakit yang paling luas diakui oleh dokter Tiongkok, diterbitkan setiap tahun oleh institut manajemen rumah sakit Universitas Fudan.

  1. West China Hospital, Sichuan University

    Chengdu

    Spesialisasi klinis kunci nasional

    Juga diperingkat: Bedah Umum #3, Bedah Toraks #4, Urologi #2 (seri) dalam daftar Fudan.

  2. Cancer Hospital of Chinese Academy of Medical Sciences

    Beijing

    Spesialisasi klinis kunci nasional

    Riset yang diterbitkan

    PubMed mengindeks 1 makalah tentang penyakit ini yang menyebut rumah sakit ini.

    Juga diperingkat: Bedah Toraks #1, Onkologi Medis #1, Urologi dinominasikan dalam daftar Fudan.

  3. China-Japan Friendship Hospital

    Beijing

    Spesialisasi klinis kunci nasional

    Riset yang diterbitkan

    1 studi terbit lainnya

    PubMed mengindeks 3 makalah tentang penyakit ini yang menyebut rumah sakit ini.

    Juga diperingkat: Pulmonologi #2, Bedah Toraks dinominasikan dalam daftar Fudan.

  4. Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

    Wuhan

    Spesialisasi klinis kunci nasional

    Juga diperingkat: Bedah Umum #6, Urologi #5, Ginekologi #2 dalam daftar Fudan.

  5. Shaanxi Provincial People's Hospital

    Xi'an

    Spesialisasi klinis kunci nasional

    Riset yang diterbitkan

    PubMed mengindeks 2 makalah tentang penyakit ini yang menyebut rumah sakit ini.

Uji klinis (pengobatan dalam penelitian)

Selain perawatan standar, studi riset klinis untuk Stomach cancer mungkin sedang terbuka bagi peserta di Tiongkok. Pengobatan yang diteliti belum disetujui regulator sebagai terapi standar — itu riset klinis, bukan perawatan rutin. Setiap catatan menyebutkan peneliti utama dan rumah sakit yang menjalankan studi itu. Bila Anda berminat, hubungi rumah sakit untuk menanyakan kelayakan dan tentukan sendiri apakah ingin mendaftar.

  1. Studi Preliminary Study on the Diagnostic Value Comparison of 18F-FAPI-04 PET/CT and PET/MR in Gastric Cancer

    Peneliti utama
    Hui Ye · Professor
    Rumah sakit
    Hunan Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT06543108

  2. Studi The Effect of Perioperative Rehabilitation Programme Delivered Via a Smart Phone Based Digital Platform in Patients Undergoing Neoadjuvant Therapy for Gastric Cancer Surgery: Study Protocol for a Randomised Controlled Trial

    Peneliti utama
    JunZhang · Chief Surgeon
    Rumah sakit
    Beijing Friendship Hospital, Capital Medical University
    Status
    Sedang merekrut
    Registri
    NCT07441850

  3. Studi Fluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer: A Multicenter Randomized Controlled Trial Study

    Rumah sakit
    Beijing Friendship Hospital, Capital Medical University
    Status
    Sedang merekrut
    Registri
    NCT06788548

  4. Studi The Study of Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Initial Unresectable Local Advanced or Potentially Resectable Metastatic Gastric Adenocarcinoma

    Peneliti utama
    Zhaode Bu · Clinical Professor
    Rumah sakit
    Peking University Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT04047953

  5. Studi Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer: A Community-Based Randomized Controlled Trial

    Rumah sakit
    Peking University Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT06306755
60 studi terdaftar lainnya

  1. Studi Prospective Cohort Study on the Efficacy, Adverse Effects, and Biomarkers of First-Line/Neoadjuvant Therapy With Immune Checkpoint Inhibitors Combined With Chemotherapy in Advanced Gastric Cancer

    Peneliti utama
    Lian Liu, MD, PHD · Professor, Chief Physician
    Rumah sakit
    Qilu Hospital of Shandong University
    Status
    Sedang merekrut
    Registri
    NCT06727981

  2. Studi A Study on the Safety and Efficacy of Leucine-Restricted Diet in Gastric Cancer Patients Treated With Neoadjuvant Chemotherapy and Immunotherapy

    Rumah sakit
    Qilu Hospital of Shandong University
    Status
    Sedang merekrut
    Registri
    NCT07537361

  3. Studi Exploratory Study of NK510 Cell Therapy in the Treatment of Recurrent and Refractory Advanced Gastric Cancer and Colorectal Cancer

    Rumah sakit
    Nanjing Drum Tower Hospital
    Status
    Sedang merekrut
    Registri
    NCT07166263

  4. Studi Phase Ⅱ Study of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis

    Rumah sakit
    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Status
    Sedang merekrut
    Registri
    NCT06685887

  5. Studi Diagnostic and Predictive Performance of Dual-/ Muti- Energy CT and MRI in the Treatment Response and Survival Prognosis of Gastric Cancer

    Peneliti utama
    Zihao Zhao · The First Affiliated Hospital of Zhengzhou University
    Rumah sakit
    First Affiliated Hospital of Zhengzhou University
    Status
    Sedang merekrut
    Registri
    NCT06869694

  6. Studi Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Adenocarcinoma of the Gastric and Oesophagogastric Junction: an Open-label, Prospective, Multicenter, Randomised, Phase 2 Trial.

    Rumah sakit
    The Sixth Affiliated Hospital, Sun Yat-sen University
    Status
    Sedang merekrut
    Registri
    NCT06510010

  7. Studi Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Gastric Cancer

    Status
    Sedang merekrut
    Registri
    NCT06979895

  8. Studi The Application and Effect of Goal-oriented Albumin Infusion in the Control of Postoperative Complications in Patients With Gastric Cancer - a Single-center Prospective Non- Randomized Controlled Study

    Peneliti utama
    Yuchen Guo, Ph.D. · Prof.
    Rumah sakit
    The First Hospital of Jilin University
    Status
    Sedang merekrut
    Registri
    NCT07119463

  9. Studi Establishing an Innovative Cohort for Chinese Early Gastric Cancer Patients Based on the National Clinical Research Center for Digestive Diseases Prospective Database: A Retrospective Study

    Peneliti utama
    JunZhang · Chief Surgeon
    Rumah sakit
    Beijing Friendship Hospital, Capital Medical University
    Status
    Sedang merekrut
    Registri
    NCT07747688

  10. Studi A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer with SOX Plus Tislelizumab Combined with HIPEC

    Peneliti utama
    Yan Shi
    Status
    Sedang merekrut
    Registri
    NCT06760858

  11. Studi A Multicenter, Prospective, Randomized Controlled Clinical Study of Robotic Versus Laparoscopic Radical Surgery for Locally Advanced Gastric Cancer

    Peneliti utama
    Yan Shi
    Status
    Sedang merekrut
    Registri
    NCT06791538

  12. Studi Comparison of Gastroesophageal Reflux and Quality of Life Between Double-tract and Tubular Gastric Anastomosis in Proximal Gastric Cancer Patients

    Rumah sakit
    Qilu Hospital of Shandong University
    Status
    Sedang merekrut
    Registri
    NCT07635836

  13. Studi A Study on the Safety and Efficacy of Leucine-Restricted Diet in Gastric Cancer Patients Treated With Chemotherapy and Immunotherapy

    Rumah sakit
    Qilu Hospital of Shandong University
    Status
    Sedang merekrut
    Registri
    NCT07537348

  14. Studi A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer

    Rumah sakit
    Jiangsu Province Hospital
    Status
    Sedang merekrut
    Registri
    NCT06555471

  15. Studi The Clinical Significance of Examining Metastatic Lymph Nodes in Respective Gastric Mesenteries in the Gastric Cancer Patients Who Received D2 Lymphadenectomy Plus Complete Mesogastric Excision

    Peneliti utama
    Jichao Qin · professor
    Rumah sakit
    The First Affiliated Hospital, Zhejiang University School of Medicine
    Status
    Sedang merekrut
    Registri
    NCT07139418

  16. Studi A Prospective Cohort Study on Serum Immune Protein Signature for Predicting Neoadjuvant Therapy Efficacy in Advanced Gastric Cancer

    Rumah sakit
    Zhongshan Hospital
    Status
    Sedang merekrut
    Registri
    NCT06662110

  17. Studi A Randomized，Multicenter, Open-Label，Phase II/III Study to Evaluate the Safety and Efficacy of Disitamab Vedotin Combined With Cadonilimab in Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Adenocarcinoma Who Have Progressed on r First-line Therapy

    Rumah sakit
    Peking University Cancer Hospital
    Status
    Sedang merekrut
    Registri
    NCT06221748

  18. Studi Single Center, Phase II Clinical Study of PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer

    Rumah sakit
    Peking University Third Hospital
    Status
    Sedang merekrut
    Registri
    NCT06792162

  19. Studi A Prospective, Single-Arm, Phase Ⅱ Clinical Trial Evaluating Fruquintinib in Combination With Paclitaxel for Injection (Albumin-bound) and Iparomlimab and Tuvonralimab Injection as Second-Line Therapy in Advanced Gastric Cancer Patients Previously Received Immunotherapy

    Peneliti utama
    Dai, Guanghai · Professor,Chief Physician
    Rumah sakit
    Chinese PLA General Hospital
    Status
    Sedang merekrut
    Registri
    NCT07392346

  20. Studi Fecal Microbiota Transplantation Combined with SOX and Sintilimab As First-line Treatment for Advanced Gastric Cancer:A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study (FMT-JSNO-01)

    Peneliti utama
    Hua Jiang · MD
    Rumah sakit
    Changzhou No.2 People's Hospital
    Status
    Sedang merekrut
    Registri
    NCT06405113

  21. Studi Perioperative S-1 Plus Oxaliplatin Combined With Serplulimab or Placebo for Locally Advanced Gastric Adenocarcinoma With Proficient Mismatch Repair: a Prospective, Multi-center, Double-blinded, Randomized Placebo-controlled Study

    Peneliti utama
    Yu jiren · Professor
    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Sedang merekrut
    Registri
    NCT05872685

  22. Studi A Prospective, Multicentre, Double-blind Randomized Controlled Clinical Study of the Efficacy and Safety of Taurine Combined With Serplulimab and Chemotherapy Versus Serplulimab Combined With Chemotherapy for Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

    Rumah sakit
    Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
    Status
    Sedang merekrut
    Registri
    NCT06128252

  23. Studi A Radio-Pathomic Multimodal Machine Learning Model for Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Advanced Gastric Cancer: A Retrospective Observational Study

    Rumah sakit
    The Sixth Affiliated Hospital, Sun Yat-sen University
    Status
    Sedang merekrut
    Registri
    NCT06451393

  24. Studi A Single-arm, Open-label, Multicenter Phase 2 Study to Evaluate XELOX + Tislelizumab in Combination With Doxorubicin Hydrochloride Liposome Injection （XELOX+PD-1+PLD）as Neoadjuvant Therapy for Resectable Gastric Cancer

    Peneliti utama
    Qi Li · Chief Physician
    Rumah sakit
    Shanghai General Hospital
    Status
    Sedang merekrut
    Registri
    NCT05536102

  25. Studi A Multicenter, Prospective, Observational Cohort Study to Assess the Safety and Efficacy of Robotic Assisted Surgery Using Vessel Sealer Extend in Locally Advanced Gastric Cancer (STARS-GC09)

    Peneliti utama
    Quan Wang · Director, Clinical Professor
    Rumah sakit
    The First Hospital of Jilin University
    Status
    Sedang merekrut
    Registri
    NCT06881043

  26. Studi Clinical Study on the Efficacy and Safety of Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression

    Rumah sakit
    Tianjin Medical University Cancer Institute & Hospital
    Status
    Sedang merekrut
    Registri
    NCT06560528

  27. Studi Samples Procurement for Patients With Colorectal Cancer, Gastric Cancer, and Non-malignant Disease Undergoing Surgery

    Peneliti utama
    Tao Fu · Director of Department of GI Surgery II
    Rumah sakit
    Renmin Hospital of Wuhan University
    Status
    Sedang merekrut
    Registri
    NCT03972956

  28. Studi A Prospective, Multicenter, Randomized, Controlled Study of the Clinical Efficacy of Robotic and Laparoscopic Radical Gastrectomy in Neoadjuvant Gastric Cancer Patients

    Rumah sakit
    The Affiliated Hospital of Qingdao University
    Status
    Sedang merekrut
    Registri
    NCT06042998

  29. Studi Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer: a Single-arm, Open Clinical Study

    Rumah sakit
    The First Affiliated Hospital of Fujian Medical University
    Status
    Sedang merekrut
    Registri
    NCT06791083

  30. Studi Development and Validation of an Explainable Artificial Intelligence Model for Early Gastric Cancer Diagnosis Using Multimodal Endoscopic Imaging

    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Sedang merekrut
    Registri
    NCT07551466

  31. Studi A Phase II, Open-Label, Multicenter Trial Comparing Disitamab Vedotin Plus Sintilimab and S-1 With Trastuzumab Plus Chemotherapy ± Sintilimab for First-Line Treatment of HER2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (RCTS2)

    Peneliti utama
    Lian Liu, MD, PHD · Director
    Rumah sakit
    First Affiliated Hospital of Zhengzhou University
    Status
    Sedang merekrut
    Registri
    NCT06730373

  32. Studi Efficacy and Safety of Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids in Gastric Cancer Malignant Ascites: a Phase I/II Clinical Study (IPIZA)

    Peneliti utama
    Lian Liu, MD, PHD · Professor
    Rumah sakit
    Qilu Hospital of Shandong University
    Status
    Sedang merekrut
    Registri
    NCT06759064

  33. Studi A Prospective, Randomised Placebo Controlled Trial of Faecal Microbiota Transplantation in Patients With Advanced Gastric Cancer

    Peneliti utama
    Xiangyu Kong
    Status
    Sedang merekrut
    Registri
    NCT06346093

  34. Studi A Randomized, Controlled, Open-Label, Multicenter Clinical Trial Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression

    Rumah sakit
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Sedang merekrut
    Registri
    NCT07788196

  35. Studi Prospective, Phase II Clinical Study of Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer

    Rumah sakit
    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Status
    Sedang merekrut
    Registri
    NCT06487429

  36. Studi Clinical Study of SHR1701 in Combination With CAPOX and SHR2554 or Apatinib for First-line Treatment of Advanced Gastric Cancer

    Peneliti utama
    Yongxu Jia · Chief Investigator
    Rumah sakit
    First Affiliated Hospital of Zhengzhou University
    Status
    Sedang merekrut
    Registri
    NCT07294664

  37. Studi Lymph Node Metastasis and Tumor Deposit in the Short Gastric Mesentery Following Total Gastrectomy With D2 Lymphadenectomy Plus Complete Mesogastric Excision for Gastric Cancer: A Prospective Observational Study

    Peneliti utama
    Jichao Qin · Professor
    Rumah sakit
    The First Affiliated Hospital, Zhejiang University School of Medicine
    Status
    Sedang merekrut
    Registri
    NCT06728878

  38. Studi Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer : a Phase Il Study

    Peneliti utama
    Zhongguang Luo, MD · Chief Physician
    Rumah sakit
    Huashan Hospital
    Status
    Sedang merekrut
    Registri
    NCT06054906

  39. Studi A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer

    Peneliti utama
    YiHui Guan · Professor
    Rumah sakit
    Huashan Hospital
    Status
    Sedang merekrut
    Registri
    NCT07707531

  40. Studi Detection of Peritoneal Metastasis of Gastric Cancer by Liquid Biopsy in Peripheral Blood: A Prospective Study

    Rumah sakit
    Zhongshan Hospital
    Status
    Sedang merekrut
    Registri
    NCT05347524

  41. Studi Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric：MetBio-GC

    Rumah sakit
    Ruijin Hospital
    Status
    Sedang merekrut
    Registri
    NCT07076979

  42. Studi A Phase 1/1b Study of ASP2138 as Monotherapy and in Combination With Pembrolizumab and mFOLFOX6 or Ramucirumab and Paclitaxel in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination With mFOLFIRINOX in Participants With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression

    Rumah sakit
    Sun Yat-sen University Cancer Center
    Status
    Sedang merekrut
    Registri
    NCT05365581

  43. Studi The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial

    Peneliti utama
    Lin Chen · Prof.
    Rumah sakit
    Chinese PLA General Hospital
    Status
    Sedang merekrut
    Registri
    NCT07212933

  44. Studi Effect of Family-Supervised Multimodal Prehabilitation Throughout Preoperative Neoadjuvant Chemotherapy on Clinical Outcomes in Gastric Cancer Patients: A Single-Center Randomized Controlled Trial

    Peneliti utama
    Zhou Yanbing · Chief Physician, Affiliated Hospital of Qingdao University
    Rumah sakit
    The Affiliated Hospital of Qingdao University
    Status
    Belum merekrut
    Registri
    NCT07183358

  45. Studi Efficacy and Safety of Beta-Blockers Combined With Neoadjuvant Immunotherapy for Locally Advanced Gastric Cancer: an Open-lable, Single-arm Study

    Rumah sakit
    Nanfang Hospital
    Status
    Belum merekrut
    Registri
    NCT07511894

  46. Studi Multicenter Randomized Controlled Clinical Study on Acupuncture Combined With Adjuvant Chemotherapy for the Prevention of Recurrence and Metastasis After Gastric Cancer Surgery

    Rumah sakit
    The First Affiliated Hospital, Sun Yat-sen University
    Status
    Belum merekrut
    Registri
    NCT07098949

  47. Studi A Randomized Controlled Study of Endoscopic Cryoablation Combined With PD-1 Inhibitor for Maintenance Therapy in Advanced Gastric Cancer

    Peneliti utama
    Zhongguang Luo, MD · Chief Physician
    Rumah sakit
    Huashan Hospital
    Status
    Belum merekrut
    Registri
    NCT06957977

  48. Studi A Prospective Exploratory Study of a HIPEC Priming Strategy Followed by Serplulimab Combined With SOX/XELOX as Neoadjuvant Therapy for Locally Advanced Gastric Cancer

    Peneliti utama
    weijun wang
    Status
    Belum merekrut
    Registri
    NCT07621484

  49. Studi Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Open-Label, Randomized, Multi-Centered Phase III Trial

    Peneliti utama
    Yihong Sun · Chief of Gastrointestinal Surgery Department
    Rumah sakit
    Zhongshan Hospital
    Status
    Belum merekrut
    Registri
    NCT07508956

  50. Studi A Single-arm, Open-label Phase I/II Study to Evaluate the Safety and Preliminary Efficacy of Hypoxia-Inducible CD73/AXL-Targeting CAR-T Cells (XW-LTH-03) in Patients With Advanced Gastric Cancer

    Rumah sakit
    Zhongshan Hospital
    Status
    Belum merekrut
    Registri
    NCT07333573

  51. Studi A Multicenter, Prospective, Real-world Study Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer

    Peneliti utama
    Zheng Zhichao · Offices Director
    Rumah sakit
    Liaoning Cancer Hospital
    Status
    Belum merekrut
    Registri
    NCT07132528

  52. Studi A Multicenter, Prospective, Real-world Study Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery

    Peneliti utama
    Zheng Guoliang · Vice Offices Director
    Rumah sakit
    Liaoning Cancer Hospital
    Status
    Belum merekrut
    Registri
    NCT07149181

  53. Studi A Single-centre Phase II Clinical Study of Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction Adenocarcinoma

    Peneliti utama
    Zheng Zhichao · Offices Director
    Rumah sakit
    Liaoning Cancer Hospital
    Status
    Belum merekrut
    Registri
    NCT06764251

  54. Studi A Prospective, Multicenter, Randomized, Controlled Study of the Clinical Efficacy of Robotic and Laparoscopic Radical Total Gastrectomy in Locally Advanced Middle and Upper Gastric Cancer

    Peneliti utama
    Chang-Ming Huang, Prof. · Professor
    Rumah sakit
    Fujian Medical University Union Hospital
    Status
    Belum merekrut
    Registri
    NCT05235932

  55. Studi A Prospective, Multicenter, Phase III Randomized Controlled Trial Evaluating the Impact of Radical Surgery Versus Non-Surgery on Prognosis and Quality of Life in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy (ALANO Study, CGCA2603 Study)

    Peneliti utama
    Hua Huang, MD, PhD · Professor, Department of Gastric Surgery, Fudan University Shanghai Cancer Center
    Rumah sakit
    Peking University Cancer Hospital
    Status
    Belum merekrut
    Registri
    NCT07789184

  56. Studi Effect of Prophylactic Hyperthermic Intraperitonal Chemotherapy（HIPEC）After Radical Surgery on Long-term Survival for Locally Advanced Gastric Cancer（cT3N+M0 and cT4aN+/-M0）: A Randomized-controlled Study

    Rumah sakit
    The First Hospital of Jilin University
    Status
    Belum merekrut
    Registri
    NCT06525714

  57. Studi TACE Combined With Thermal Ablation and Antibody-drug Conjugates, Immune Checkpoint Inhibitors, and Chemotherapy as First-line Treatment for HER2-highly-expressing Gastric Cancer With Liver Metastases: a Multicenter, Single-arm Prospective Clinical Study.

    Rumah sakit
    Shandong Provincial Hospital
    Status
    Belum merekrut
    Registri
    NCT07602140

  58. Studi Clinical Efficacy and Safety Evaluation of Submucosal Injection of Indocyanine Green Tracer in 3D Fluorescent Laparoscopic Lymph Node Dissection for Gastric Cancer: a Prospective, a Multicenter, Randomized, Controlled Study Clinical Trial

    Peneliti utama
    Wenbin Yu · Professor， and Chief of Gastrointestinal Surgery Department
    Rumah sakit
    Qilu Hospital of Shandong University
    Status
    Belum merekrut
    Registri
    NCT06421220

  59. Studi A Prospective, Single-center, Phase II Clinical Study of First-line Treatment for HER2 (Human Epidermal Growth Factor Receptor 2) Overexpressing Advanced Gastric Cancer With Disitamab Vedotin in Combination With Cadonilimab

    Peneliti utama
    Yongxu Jia · Chief Physician
    Rumah sakit
    First Affiliated Hospital of Zhengzhou University
    Status
    Belum merekrut
    Registri
    NCT06492317

  60. Studi Liposomal Irinotecan in Combination with Sintilimab in Second-Line Treatment of Progressive Gastric Cancer, a Single-Arm, Single-Center, Open-Label, Phase II Clinical Study

    Peneliti utama
    Hao Li · Principal Investigator
    Rumah sakit
    Ruijin Hospital
    Status
    Belum merekrut
    Registri
    NCT06697366

Halaman ini hanya membagikan informasi studi yang terdaftar secara publik. Halaman ini tidak menganjurkan atau mendorong keikutsertaan dalam studi mana pun. Keikutsertaan sepenuhnya sukarela dan risiko pengobatan yang belum disetujui tidak diketahui; hubungi rumah sakit langsung untuk kelayakan dan rincian persetujuan setelah penjelasan.

Terapi lanjutan: apa yang sudah berizin dan apa yang masih dalam uji klinis

Rumah sakit dengan catatan spesialisasi kunci nasional

Tampilkan catatan rumah sakit 5 rumah sakit dengan catatan spesialisasi kunci

Setiap baris adalah rumah sakit dengan catatan spesialisasi klinis kunci nasional pada spesialisasi tempat penyakit ini dikelompokkan. Ini catatan daftar terbit, bukan rekomendasi dan bukan peringkat.

Rumah sakit Kota Spesialisasi (sebagaimana diterbitkan) Bukti Sumber
Cancer Hospital of Chinese Academy of Medical Sciences Beijing Bedah Gastrointestinal Tingkat B https://www.cicams.ac.cn/news/401.html
China-Japan Friendship Hospital Beijing Bedah Gastrointestinal Tingkat B https://www.zryhyy.com.cn/zryh/c100020/202309/47e8245aa93343baac89762d4e80580f.shtml
West China Hospital, Sichuan University
Tier 3 · TERTINGGI
 Chengdu Bedah Gastrointestinal Tingkat A https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
Tier 3 · TERTINGGI
 Wuhan Bedah Gastrointestinal Tingkat B https://www.tjh.com.cn/contents/934/27291.html
Shaanxi Provincial People's Hospital Xi'an Bedah Gastrointestinal Tingkat B https://www.spph-sx.com/zlfw1/zdzk.htm

5 rumah sakit dengan catatan spesialisasi kunci nasional yang cocok.

Nilai yang ditulis dalam bahasa Tiongkok dikutip sebagaimana diterbitkan oleh sumber.

Apa yang dilaporkan pasien

Hanya angka agregat: hasil nasional yang dikutip dengan sumbernya dan tahun yang dirujuknya. Ini bukan testimoni pasien dan bukan pernyataan tentang satu orang.

  • Sebagaimana dilaporkan dalam National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) (2023): National inpatient satisfaction / outpatient satisfaction — 95.42 / 93.95 score, 0-100.

    National aggregate across the 2,168 tertiary public hospitals that took part in the national performance monitoring (all conditions combined; not disease-specific, not hospital-specific).

    Sumber: National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) — https://www.gov.cn/zhengce/zhengceku/202503/content_7016208.htm — 2023 — Tingkat A

Semua topik terapi & akses

Pertanyaan tentang penyakit ini

Kami tidak dapat memberikan nasihat medis, tetapi kami dapat menjawab pertanyaan tentang halaman ini dan tentang mengatur pengobatan di Tiongkok.

Tanyakan kepada kami tentang kondisi ini

Kode ICD

Tampilkan tabel kode 10 kode ICD
Versi Kode Nama dalam versi itu
ICD-10-WHO C16 Malignant neoplasm of stomach
ICD-10-WHO C16.0 Cardia
ICD-10-WHO C16.1 Fundus of stomach
ICD-10-WHO C16.2 Body of stomach
ICD-10-WHO C16.3 Pyloric antrum
ICD-10-WHO C16.4 Pylorus
ICD-10-WHO C16.5 Lesser curvature of stomach, unspecified
ICD-10-WHO C16.6 Greater curvature of stomach, unspecified
ICD-10-WHO C16.8 Overlapping lesion of stomach
ICD-10-WHO C16.9 Stomach, unspecified

Baris-barisnya adalah entri ICD-10 WHO untuk penyakit ini, dikutip sebagaimana diterbitkan.

Sumber & bukti

URL sumber
https://wjw.fujian.gov.cn/xxgk/fgwj/zxwj/201904/P020190412506737868905.xlsx
Skema sumber
https
Jenis sumber
Komisi kesehatan provinsi
Tingkat bukti
A - dinyatakan oleh komisi kesehatan, lembaga riset nasional, atau universitas
Diambil pada
2026-09-24